Enjoy complimentary customisation on priority with our Enterprise License!
A cephalosporin is a group of bacterial antibiotics that bind to the penicillin-binding bacterial protein so as to inhibit the synthesis of the bacterial cell wall. The global market for cephalosporin drugs is positively influenced by factors like the immediate availability of treatment measures in developed nations, which results in its slow but steady market growth rate of more than 3% by 2019.
Technavio’s market research analyst has estimated the APAC region to account for a market share of more than 58% during the forecast period. The augmented demand for a better healthcare infrastructure in this region is expected to drive cephalosporin market growth in APAC during the next four years.
In this market research report, analysts estimate the injection segment to be the most preferred route of drug administration as it results in rapid drug delivery. Its usefulness in replacing fluids, delivering chemotherapeutic drugs, and performing blood transfusions results in its high popularity during the forecast period.
This cephalosporin drugs market is characterized by the presence of many large and small vendors who continually compete with each other to gain maximum traction in this market. A company that can manufacture and market highly efficient and safe cephalosporin drugs is expected to gain a competitive edge in this market.
Key vendors analyzed in this market are -
Other prominent vendors are Abbott, Aspen Pharmacare, AstraZeneca, Aurobindo Pharma, Basilea Pharmaceuticals, Baxter, Biocon, Corden Pharma, Eli Lilly, F. Hoffmann-La Roche, Flynn Pharma, Hospira, Incepta Pharmaceuticals, Johnson & Johnson, Kyorin Pharmaceutical, Lupin Pharmaceuticals, Orchid Pharma, Par Pharmaceutical, Pernix Therapeutics, Sanofi, Shionogi, Sun Pharmaceutical, Takeda Pharma, Theravance Biopharma, and Wockhardt.
Technavio market research analysts envisage upcoming trends, such as the increasing use of combination therapies, to bolster market growth during the forecast period. The increasing approval of combination drugs is a significant trend in this market as they have better efficacy rates compared to monotherapies. Additionally, the recent approvals of drugs like Zerbaxa and Avycaz by the US FDA is expected to spur market growth during the forecast period.
This report provides a number of factors contributing to the adoption, limitations, and opportunities of the global cephalosporin drugs market. It also offers an analysis of each factor and an estimation of the extent to which the factors are likely to impact the overall market growth.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Cephalosporin overview
Introduction
Precursors of cephalosporins
Mechanism of action
General principles for the use of antibiotics
Clinical uses
Epidemiology
PART 06: Overview on the consumption of antibiotics
Latin America
Europe
APAC
PART 07: Legislation relating to antibiotic use in the US
PART 08: Market landscape
Market Overview
Market size and forecast
Five forces analysis
PART 09: Market segmentation by generation of cephalosporin
First generation cephalosporins
Second generation cephalosporins
Third generation cephalosporins
Fourth generation cephalosporins
Fifth generation cephalosporins
PART 10: Market segmentation by route of administration
Injection
Oral
PART 11: Geographical segmentation
Segmentation of global cephalosporin drugs market by geography
Cephalosporin drugs market in Americas
Cephalosporin drugs market in EMEA
Cephalosporin drugs market in APAC
PART 12: Market drivers
Special regulatory designation for pipeline molecules
Rise in prevalence of infectious diseases
Increase in awareness
PART 13: Impact of drivers
PART 14: Market challenges
Development of drug resistance
High generic penetration
Weak pipeline
PART 15: Impact of drivers and challenges
PART 16: Market trends
Use of combination therapies
Increase in mergers and acquisitions
Increasing irrational use of cephalosporins
PART 17: Vendor landscape
Competitive Scenario
Market Share Analysis 2014
Other prominent vendors
PART 18: Key vendor analysis
Allergan
Astellas
BMS
GSK
Merck
Pfizer
Sandoz
Teva Pharmaceuticals
PART 19: Appendix
List of abbreviation
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.